TB-500
TB-500: FDA status after the July 2026 advisory vote, why thymosin beta-4 studies do not transfer, sport bans and sourcing risks.
Not FDA-approved · Evidence grade D · Reviewed
TB-500 (Thymosin beta-4 fragment). Synthetic peptide.
DNot FDA-approved. Evidence grade D: animal and lab data only.
What is TB-500?
TB-500 is a synthetic version of a fragment of thymosin beta-4, promoted for tissue repair. It is often sold alongside BPC-157.
Is TB-500 FDA-approved?
Not approved for any use. In July 2026 an FDA advisory committee narrowly recommended adding it to the list of substances pharmacies may compound. The vote is advisory. It is not FDA approval, and nothing changes legally until FDA finishes rulemaking. The use the committee considered was wound healing.
What does the evidence show for TB-500?
No published human trials of TB-500 itself. FDA has pointed out that human studies of thymosin beta-4 are not evidence for TB-500.
What are the known risks of TB-500?
Safety in people is unknown. It is banned in sport at all times under the World Anti-Doping Code.
How is TB-500 measured?
Blend vials that combine it with BPC-157 can be entered using the second-compound field. Products sold online as "research use only" have no assurance of identity, dose or sterility. The calculator can do the arithmetic for any vial, but it cannot tell you what is actually in one.
Sources: AJMC: FDA panel backs 6 peptides for compounding; Black Health: what the FDA peptide vote changed; Worst Pills, Best Pills: unapproved peptides. This profile does not recommend any dose or use.
For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.